Botulinum Toxin Therapy for Movement Disorders in Patients Aged 2 to 100 Years Treatment Including Various Involuntary Muscle Spasms and Movement Conditions

What this Trial Is About

Researchers are studying the use of botulinum toxin BTX for treating various involuntary muscle spasms and movement disorders. This observational study focuses on patients with movement disorders such as dystonia, hemifacial spasm, blepharospasm, tremor, tics, spasticity, and more. The study aims to follow the natural history of these patients receiving standard BTX injections and to provide BTX treatment for participants in other NIH research projects. Participants aged 2 years and older with movement disorders that might benefit from BTX injections are included. The treatment is tailored to each patients condition using specific injection techniques, including guidance methods like EMG and ultrasound. The study also trains physicians in the preparation and handling of BTX therapy to ensure proper administration. Throughout the study, participants receive standard BTX injections and are monitored for their response and disease progression. Data collection helps maintain a cohort of patients with stable BTX treatment responses for ongoing and future research. The study tracks natural history and treatment outcomes over time, supporting further understanding of BTX use in movement disorders.

Botulinum Toxin for the Treatment of Involuntary Movement Disorders